Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

Fig. 5

Trabectedin and olaparib combination showed antitumor effects in in vivo models. a-b, Tumor volume and c-d, histological analysis of proliferating cells (PCNA staining), DNA damage (P-H2AX), and apoptosis (TUNEL) in DMR and SJSA-1 s.c. xenografted NOD/SCID mice treated with trabectedin and olaparib, as single agent and in combination or untreated. e-f, in vivo imaging of tumor growth and spread in orthotopic uterine leiomyosarcoma model and g-h, tumor colony growth in e.v. SJSA xenografted NOD/SCID mice treated with trabectedin and olaparib as single agents and in combination, or left untreated; in vivo imaging was done 3 days after the end of the 21-day- treatment; Y error bars indicate mean ± S.E.M; *p < 0.05; **p < 0.01; *** p < 0.001

Back to article page

Molecular Cancer

ISSN: 1476-4598